Could we use a serum level of glycine as a prognostic factor of its efficacy in schizophrenic patients?;Czy osoczowe stȩżenia glicyny moga̧ być czynnikiem rokowniczym skuteczności jej stosowania u chorych na schizofreniȩ?

Psychiatria Polska

Volumn 44, Issue 3, 2010, Pages 395-404

  Strzelecki, Dominik ^a   Rabe Jabłońska, Jolanta ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Glycine; NMDA; Schizophrenia

Indexed keywords

AMINO ACID; GLYCINE; NEUROLEPTIC AGENT;

ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; PROGNOSIS; PSYCHOLOGIC TEST; SCHIZOPHRENIA; WISCONSIN CARD SORTING TEST; ADULT; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; HOSPITALIZATION; MALE; PROSPECTIVE STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TREATMENT OUTCOME;

ADULT; AMINO ACIDS; ANTIPSYCHOTIC AGENTS; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLYCINE; HUMANS; MALE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77956832516     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Carlsson A, Waters N, Waters S, Carlsson ML. Network interactions in schizophrenia - therapeutic implications. Brain Res. Brain Res. Rev. 2000; 31: 342-349.
2. Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. 1999; 33: 523-533.
3. Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacol. 1995; 13: 9-19.
4. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacol. 2001; 25: 455-467.
5. Strzelecki D, Rabe-Jabłońska J. Rola zaburzeń funkcji układu glutaminianergicznego w patogenezie schizofrenii. Psychiatr. Psychol. Klin. 2004; 1: 4-11.
6. Strzelecki D, Rabe-Jabłońska J. Glicyna i jej znaczenie w terapii schizofrenii. Post. Psychiatr. Neurol. 2003; 12: 193-200.
7. Strzelecki D, Rabe-Jabłońska J. Transportery glicyny - potencjalny cel interwencji farmakologicznej w leczeniu schizofrenii. Post. Psychiatr. Neurol. 2006; 15: 117-120.
8. Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizofrenia: a systematic review and meta-analysis. Schizophr. Res. 2005; 72: 225-234.
9. Neeman G, Blanaru M, Bloch B, Kremer I, Ermilov M, Javitt DC, Heresco-Levy U. Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. Am. J. Psychiatry 2005; 162: 1738-1740.
10. D'Souza DC, Gil R, Cassello K, Morrissey K, Abi-Saab D, White J i in. IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biol. Psychiatry 2000; 47: 450-462.
11. Leiderman E, Zylberman I, Zuckin SR, Cooper TB, Javitt DC. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial. Biol. Psychiatry 1996; 39: 213-215.
12. Sumiyoshi T, Anil Elif A, Yin D, Jayathialke K, Lee M, Meltzer HY. Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. Int. J. Neuropsychopharmacol. 2004; 7: 1-7.